dipyridamole / Generic mfg. - LARVOL DELTA

Mulberroside A inhibits NLRP6 to prevent alveolar macrophage efferocytosis and lung-derived SAA3-platelet transport in high fructose-induced hippocampal inflammation. (PubMed, Phytomedicine) - "These results suggested that mulberroside A inhibited NLRP6 to prevent alveolar macrophage efferocytosis and lung-derived SAA3-platelet transport in high fructose-induced hippocampal inflammation."

Journal • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • NLRP6

Cranial Defect Reconstruction With Custom 3D-Printed Hydroxyapatite Scaffolds Augmented With rhBMP-2 or Dipyridamole in a Nonhuman Primate Model. (PubMed, J Tissue Eng Regen Med) - "Reconstructing critically sized cranial defects with custom 3D-printed hydroxyapatite scaffolds was successful and yielded favorable results in this model. Scaffolds augmented with rhBMP-2 demonstrated superior bone ingrowth, integration, and mechanical properties, highlighting their potential as a viable alternative to autografts and allograft materials for cranioplasty."

Journal • Preclinical • ADORA2A • BMP2

Integrative miRNA-mRNA Network and Molecular Dynamics-Based Identification of Therapeutic Candidates for Paroxysmal Nocturnal Hemoglobinuria. (PubMed, Pharmaceuticals (Basel)) - "Molecular docking and molecular dynamics simulations showed stable binding of these potential drugs to the critical molecules, indicating a viable molecular interaction foundation. Leflunomide, Dipyridamole, and Pentoxifylline may serve as promising therapeutic agents for PNH, and the hsa-miR-23a-3p/CXCL8 regulatory axis could play a pivotal role in the pathogenesis and progression of PNH."

Journal • Aplastic Anemia • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Thrombosis • CXCL12 • CXCL8 • HES1 • MIR23A

Antithrombotic agents in the treatment of severe mental illness: A systematic review and meta-analysis of randomized controlled trials. (PubMed, Neurosci Biobehav Rev) - "We included 12 randomized trials investigating aspirin, cilostazol, and dipyridamole in a total of 742 patients with schizophrenia, major depression, and bipolar disorder. The therapeutic potential of ATAs in SMI remains uncertain. Well-powered RCTs investigating clinically relevant outcomes in clearly defined populations are needed."

Journal • Retrospective data • Review • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

40 Hz flicker preconditioning protects nonarteritic anterior ischemic optic neuropathy via adenosine signaling. (PubMed, Commun Biol) - "Furthermore, neuroprotection by 40 Hz flicker was abolished by treatment with the equilibrative nucleoside transporter inhibitor dipyridamole and the A1 receptor antagonist DPCPX. These findings establish 40 Hz flicker as a non-invasive, adenosine-mediated IPC strategy, suggesting a potentially safe and translational approach for protecting against NAION and other ocular ischemic disorders."

Journal • Cardiovascular • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database. (PubMed, Expert Opin Drug Saf) - "The combination of dipyridamole and other drugs was prone to bleeding adverse events, suggesting a multifaceted safety profile that warrants careful clinical consideration. These findings underscore the need for tailored safety monitoring strategies and more nuanced risk-benefit assessments in the clinical use of dipyridamole."

Journal • Cardiovascular • Ischemic stroke • Myocardial Ischemia • Respiratory Diseases

Structural categorization and identification of electrostatic interactions in two proposed human serum albumin dimerization patterns and dipyridamole interaction. (PubMed, Turk J Chem) - "Importantly, these dimer configurations do not disrupt Sudlow's drug-binding sites, as the dipyridamole docking analysis shows strong affinity for sites I and III without affecting their utility in engineered drug delivery. Our findings open new avenues for structure-based mutagenesis and nanoparticle design strategies centered on HSA dimerization dynamics."

Journal • Oncology

Network Meta-analysis of different traditional Chinese medicine injections combined with conventional western medicine in treatment of coronary heart disease complicated with heart failure (PubMed, Zhongguo Zhong Yao Za Zhi) - ": show:(1) clinical total effective rate improvement, the top three surface under the cumulative ranking curve(SUCRA) rankings were Shuxuetong Injection + conventional western medicine, Sodium Tanshinone Ⅱ_A Sulfonate Injection + conventional western medicine, and Shuxuening Injection + conventional western medicine.(2) Left ventricular ejection fraction(LVEF) improvement, the top three SUCRA rankings were Xuesaitong Injection + conventional western medicine, Shenqi Fuzheng Injection + conventional western medicine, and Ginkgo Leaf Extract and Dipyridamole Injection + conventional western medicine.(3) Brain natriuretic peptide(BNP) reduction, the top three SUCRA rankings were Sofren Injection + conventional western medicine, Shenmai Injection + conventional western medicine, and Shuxuetong Injection + conventional western medicine.(4) N-terminal pro-brain natriuretic peptide(NT-proBNP) reduction, the top three SUCRA rankings were Shengmai Injection + conventional western..."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • CRP • NPPB

Diagnosis and treatment of multisystem amyloidosis associated with SGPL1 mutation: A case report and review of the literature. (PubMed, Medicine (Baltimore)) - "SGPL1 mutation may cause multisystem amyloidosis by disrupting S1P homeostasis and increasing monoclonal IGA-κ protein production, leading to amyloidosis. This case highlights the importance of genetic screening and an improved understanding of SGPL1 gene mutations."

Journal • Review • Amyloidosis • Cardiovascular • Dyslipidemia • Fatigue • Gastroenterology • Gastroesophageal Reflux Disease • Glomerulonephritis • Hepatology • Inflammation • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease

Parabens potential as polymer additives in supersaturable formulations. (PubMed, Pharm Dev Technol) - "This study aimed to assess two parabens, methylparaben and propylparaben, as additives to study their effects on the ability of the eudragit S100 (EU) in stabilizing the supersaturation of dipyridamole (DP)...FT-IR results demonstrated intermolecular interactions between EU and parabens which may contribute to enhancing the dissolution rate of EU. The recently revealed supersaturation improvement found in the present study is interesting and has the benefit of providing a higher drug supersaturation maintenance by polymers through the use of suitable additives."

Journal

Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK pathways. (PubMed, Arthritis Rheumatol) - "These results support a dual role for dipyridamole in RA, combining robust anti-inflammatory effects with a novel, myostatin-linked anabolic action on sarcopenia, mediated through adenosine and AMPK signaling, distinct from conventional therapeutic mechanisms."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Sarcopenia • CRP

INVESTIGATION OF DIPYRIDAMOLE-ELICITED SIGNALING IN THE BRAIN OF NIEMANN PICK TYPE C MICE: A MULTI-OMIC STUDY. (PubMed, Brain Res Bull) - "In fact, miglustat is the only approved drug and L-acetylleucine was recently granted for marketing authorization by European Medicine Agency. Interestingly, the most affected pathways in the hippocampus of Npc1-/- mice administered with DIP were those related to cGMP-PKG activation and to mitochondrial function. Our results paved the way to test DIP in experimental models of other neurodegenerative disorders, such as Alzheimer's disease that is similarly marked by hippocampal and mitochondrial dysfunctions."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Metabolic Disorders • CALB1

Drug Development. (PubMed, Alzheimers Dement) - "In summary, we demonstrated a single-cell digital twin framework for cell type-specific target identification and drug repurposing in AD and other AD-related dementia if broadly applied."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • ABCA1

Evaluating the adenosine hypothesis of Restless legs syndrome and its implications for current and future treatment strategies. (PubMed, Expert Rev Neurother) - "In this context, preliminary clinical trials with dipyridamole, an equilibrative nucleoside transporter inhibitor that enhances extracellular adenosine, showed symptomatic improvement, supporting adenosinergic enhancement as a therapeutic approach...Targeting adenosine transmission could complement existing therapies and mitigate augmentation. Future research should prioritize receptor-selective ligands, multimodal biomarkers, and controlled trials to translate this hypothesis into mechanism-based neurotherapeutic strategies."

Journal • CNS Disorders • Hematological Disorders • Movement Disorders • Restless Legs Syndrome • Sleep Disorder • ADORA2A

Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism. (PubMed, Haematologica) - "Here, we describe a novel DHODH inhibitor, JNJ-74856665, that showed strong efficacy in a subset of AML samples. The transcriptional regulator SREBF2, known to control cholesterol and lipid metabolism, was upregulated in DHODHi sensitive AMLs, and a strong synergy was observed between combination of both DHODHi and the SREBP inhibitor dipyridamole. Our data indicate that combined DHODH and SREBP inhibition is of interest to explore further as a therapeutic target option in AML."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • SREBF2

Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Pathogenicity. (PubMed, Invest Ophthalmol Vis Sci) - "DIP ameliorated intraocular inflammation, modulated Th17/Treg balance, and reduced Th17 pathogenicity in EAU, potentially via cAMP-STAT3-PIM1 signaling. These findings highlight DIP as a promising therapeutic candidate for autoimmune uveitis."

Journal • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis • CD4 • PIM1

Diagnostic Utility of Longitudinal Flow Gradient for Diagnosis of Obstructive CAD in Rubidium-82 Positron Emission Tomography. (PubMed, J Nucl Cardiol) - "Longitudinal stress MBF gradients derived from 82Rb PET may enhance diagnostic accuracy for obstructive CAD in the LAD territory. No additional diagnostic value was observed in LCX or RCA territories."

Journal • Cardiovascular • Coronary Artery Disease

From Cardiac Stress to Organ Distress: Acute Hepatorenal Dysfunction after Dipyridamole Myocardial Perfusion Imaging. (PubMed, Acta Cardiol Sin) - No abstract available

Journal • Nephrology • Renal Disease

Mycoplasma Pneumoniae-Associated Arterial Ischemic Stroke in Pediatric Patients: Clinical Manifestations and Neuroimaging Findings. (PubMed, Pediatr Neurol) - "MPP-associated AIS resulted in a poor outcome in our cohort. The frequent clinical symptoms included hemiplegic paralysis, somnolence, and aphasia. Despite timely awareness of MPP-associated stroke, current treatments (LMWH and oral aspirin) demonstrated limited efficacy."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Infectious Disease • Ischemic stroke • Pediatrics • Pneumonia • Respiratory Diseases

Blockage of the peri-synaptic Schwann cell nicotinic α7 receptor inhibitory drive increases the neuromuscular performance in rats with experimental autoimmune Myasthenia gravis: repurposing dipyridamole usage in myasthenics. (PubMed, Neuropharmacology) - "In conclusion, breaking the PSC-mediated α7nAChRs inhibitory drive with methyllycaconitine and dipyridamole may synergistically improve the neuromuscular performance and prevent fatigue in EAMG rats treated with AChE inhibitors. Therefore, we suggest repurposing the old antiplatelet vasodilator, dipyridamole, as a relatively safe add-on therapy for drug-resistant Myasthenia gravis."

Journal • Preclinical • CNS Disorders • Fatigue • Immunology • Myasthenia Gravis • Pain • SLC29A1

Impact of dual antiplatelet therapy within 72 hours post mild ischemic stroke and transient ischemic attack: meta-analysis. (PubMed, Brain Inj) - "However, the evidence regarding bleeding risk with aspirin and ticagrelor remains highly uncertain, as the estimates are imprecise with extremely wide confidence intervals, and no definitive conclusions can be drawn. Aspirin plus dipyridamole may be a safer, equally effective alternative, underscoring the need for individualized treatment based on thrombotic and hemorrhagic risks."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Ischemic stroke

Improved accuracy for myocardial blood flow mapping with deep learning-enabled CMR arterial spin labeling (DeepMASL): validation by microsphere in vivo. (PubMed, J Cardiovasc Magn Reson) - "The novel DeepMASL demonstrates much improved accuracy in the quantification of regional MBF at varying levels of coronary artery stenosis, which is correlated strongly with microsphere MBF values. The validated data indicates the potential for this DeepMASL technique to be translated for noncontrast diagnosis of myocardial perfusion deficit in a clinical setting."

Journal • Preclinical • Cardiovascular • Coronary Artery Disease

Dipyridamole alleviates necroptosis and renal inflammation via cAMP/CREB signaling pathways in septic AKI mice. (PubMed, Eur J Pharmacol) - "Dipyridamole alleviates SA-AKI by targeting PDE12, restoring cAMP signaling, and suppressing inflammation and necroptosis. These findings highlight PDE12 as a novel therapeutic target and support dipyridamole as a promising candidate for clinical translation in SA-AKI."

Journal • Preclinical • Acute Kidney Injury • Infectious Disease • Inflammation • Nephrology • Renal Disease • Septic Shock • IL6 • TNFA

Dissolution Profile of Ionizable Drugs in Biorelevant Bicarbonate Buffer at Intermediate Gastrointestinal pH Level. (PubMed, AAPS J) - "For the dissolution tests, febuxostat (FBX), dipyridamole (DPM), dantrolene Na (DNT Na), pioglitazone HCl (PIO HCl), and tosufloxacin tosylate monohydrate (TFLX TS) were employed. The dissolution profiles of ionizable drugs in BCB differed from those in CPB and ACB, especially in the case of the salt-form drugs with an acidic counterion. The floating lid method enables dissolution testing using BCB in the intermediate pH range."

Journal

Kawasaki disease shock syndrome with extreme leukemoid reaction mimicking hematologic malignancy in an IVIG-resistant child: A case report. (PubMed, Medicine (Baltimore)) - "This case emphasizes that KDSS with leukemoid reaction may mimic hematologic malignancy, delaying appropriate immunomodulatory therapy. Extreme leukocytosis (≥70 × 109/L) should not exclude KDSS, especially in children with unexplained fever and shock. Early recognition, adjunctive corticosteroid therapy, and individualized anticoagulation strategies are critical to prevent misdiagnosis and improve outcomes."

Journal • Cardiovascular • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypotension • Leukemia • Oncology • Pediatrics • Vasculitis • CRP